Shopping Cart
- Remove All
Your shopping cart is currently empty
DS-1205
🥰Excellent
Catalog No. T9123Cas No. 1855860-24-0
DS-1205 is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205 also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205 can inhibit cell migration in vitro and tumor growth in vivo[1].
DS-1205
🥰Excellent
Purity: 99.28%
Catalog No. T9123Cas No. 1855860-24-0
DS-1205 is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205 also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205 can inhibit cell migration in vitro and tumor growth in vivo[1].
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $108 | In Stock | |
| 5 mg | $272 | In Stock | |
| 10 mg | $397 | In Stock | |
| 25 mg | $738 | In Stock | |
| 50 mg | $987 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $297 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "DS-1205"
Gilteritinib
Cited
ASP2215
T44091254053-43-4
Gilteritinib (ASP2215) is a potent inhibitor of FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preclinical studies, gilteritinib demonstrated strong antileukemic and antitumor effects. Gilteritinib is currently in several Phase 3 clinical trials for acute myeloid leukemia.
- $34
Size
QTY
CitedCabozantinib S-malate
XL184, Cabozantinib Malate, Cabozantinib
T17971140909-48-3
Cabozantinib S-malate (XL184) is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity.
- $40
Size
QTY
UNC2025
UNC-2025, UNC 2025, mrx-6313
T70071429881-91-3
UNC2025 (mrx-6313)(IC50 of 0.74 nM and 0.8 nM) is a potent and orally bioavailable dual MER/FLT3 inhibitor. UNC-2025 is about 20-fold selectivity higher than Axl and Tyro3.
- $33
Size
QTY
Sitravatinib Cited
MGCD516, MG516
T43491123837-84-2
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
- $47
Size
QTY
CitedNCT-503 Cited
NCT 503
T42131916571-90-8
NCT-503 is a phosphoglycerate dehydrogenase (PHGDH) inhibitor (IC50=2.5 µM) with no activity against other dehydrogenases. NCT-503 has antitumor activity and inhibits the growth of PHGDH-dependent tumors.
- $35
Size
QTY
CitedBemcentinib Cited
R428, BGB324
T62691037624-75-1
Bemcentinib (R428) is a selective inhibitor of Axl (IC50: 14 nM) and has been investigated for the treatment of NSCLC.
- $34
Size
QTY
CitedBMS 777607 Cited
BMS-777607, BMS777607, BMS 817378
T26991025720-94-8
BMS 777607 (BMS 817378) is a Met-related inhibitor targeting c-Met, Axl, Ron, and Tyro3 with IC50 values of 3.9 nM, 1.1 nM, 1.8 nM, and 4.3 nM, respectively. BMS-777607 has been investigated in basic science research for malignant solid tumors.
- $30
Size
QTY
CitedDubermatinib
TP0903
T20051341200-45-0
Dubermatinib (TP0903) is a potent and selective Axl kinase inhibitor.
- $30
Size
QTY
G-749
G749, Denfivontinib
T26201457983-28-6
G-749, a new-type FLT3 inhibitor, exhibits effective and sustained inhibition of the FLT3 wild type and mutants.
- $40
Size
QTY
AXL-IN-13
T733002376928-82-2In house
AXL-IN-13 is a potent and orally active AXL inhibitor with an IC50 of 1.6 nM and a Kd of 0.26 nM. It exhibits anticancer activity, reverses TGF-β1-induced epithelial-mesenchymal transition (EMT), and inhibits cancer cell migration and invasion.
- $79
Size
QTY
Cabozantinib Cited
XL184, BMS-907351
T2586849217-68-1
Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM). Cabozantinib exhibits both antitumor and antiangiogenic activity.
- $39
Size
QTY
CitedSelect Batch
Purity:99.28%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | DS-1205 is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205 also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205 can inhibit cell migration in vitro and tumor growth in vivo[1]. |
| Targets&IC50 | MET:104 nM (IC50), TrkA:407 nM (IC50), Mer:63 nM (IC50), Axl:1.3 nM (IC50) |
| In vitro | DS-1205 (0.3-33 μM; 2-24 h) inhibits hGAS6-induced migration in NIH3T3-AXL cells (EC50=2.7 nM)[1]. DS-1205 (1-10000 μM; 2-24 h) significantly inhibits the phosphorylation of AXL in NIH3T3-AXL cells. DS-1205 decreases NIH3T3 cell proliferation but not obviously inhibits growth (GI50>10,000 nM)[1]. |
| In vivo | DS-1205 (3.1-50 mg/kg; p.o. bid for 5 d) exhibits pAXL inhibition mediated antitumor effects in mice[1]. |
| Molecular Weight | 735.8 |
| Formula | C41H42FN5O7 |
| Cas No. | 1855860-24-0 |
| Smiles | COc1cc(ccc1OC[C@H]1COCCO1)-c1cnc(N)c(c1)-c1ccc(NC(=O)c2cn(CC3CCOCC3)cc(-c3ccc(C)cn3)c2=O)cc1F |
| Relative Density. | 1.307 g/cm3 (Predicted) |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (61.16 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy DS-1205 | purchase DS-1205 | DS-1205 cost | order DS-1205 | DS-1205 chemical structure | DS-1205 in vivo | DS-1205 in vitro | DS-1205 formula | DS-1205 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.